FDA Moves to Keep Semaglutide and Tirzepatide Off the 503B Bulks List

How the 503B pathway works

Section 503B of the Federal Food, Drug, and Cosmetic Act created a category of registered outsourcing facilities that compound at larger scale than a traditional pharmacy and can distribute without a patient-specific prescription. Because that scale looks closer to manufacturing than to individual compounding, the rules on what they may use are correspondingly tighter.

An outsourcing facility may compound from a bulk drug substance in two main situations: the substance appears on FDA's 503B bulks list, or the drug appears on FDA's shortage list at the time of compounding, distribution, and dispensing. The shortage route is what enabled the flood of compounded semaglutide and tirzepatide between 2023 and 2025. It was always conditional, and it ended when the shortages did.

What FDA proposed and why

With the shortage route closed, the remaining structural option was to have the substances added to the 503B bulks list, which would allow bulk compounding regardless of shortage status. Nominations to that effect were submitted and FDA evaluated them.

The agency's April 30, 2026 announcement proposed not to include semaglutide, tirzepatide, or liraglutide. Its reasoning was that a determination of clinical need rests on patient safety and medical necessity, and that it did not identify sufficient evidence of such need given that FDA-approved versions of these drugs are commercially available. In plain terms: when an approved product exists and is obtainable, the agency does not see a case for outsourcing facilities to produce their own from raw powder.

Two things this proposal is not. It is not a statement that compounded GLP-1s are inherently unsafe, though FDA has separately warned about dosing errors and unapproved salt forms. And it is not final: comments closed at the end of June 2026, and the agency must weigh them before issuing a determination.

What it means in practice

For patients, the practical picture has been narrowing for a while, and this would formalize it. The large-scale compounded GLP-1 market that existed during the shortage was a product of specific, temporary conditions. Those conditions have gone, and this proposal would remove the mechanism that could have restored them.

That does not mean every compounded GLP-1 disappears. Traditional 503A pharmacies operate under a different section, and there remain narrow, legitimate patient-specific circumstances, such as a documented need for a formulation an approved product does not provide. What changes is the scale: 503B outsourcing facilities are what made bulk supply possible, and this proposal targets exactly that.

If you encounter a product marketed as compounded semaglutide or tirzepatide, the useful question is what legal basis it is being produced under. The shortage justification is no longer available. A clinician or pharmacist can help assess whether a specific arrangement is legitimate, and our guide to compounded versus FDA-approved GLP-1s covers the trade-offs in more depth.

Why this is not the peptide-compounding story

These two threads get conflated constantly, and they are different in substance. In July 2026, FDA's Pharmacy Compounding Advisory Committee recommended six of seven research peptides for the 503A bulks list, overriding its own staff reviewers. That process concerns compounds like BPC-157 and KPV, none of which is an approved drug, and it governs patient-specific compounding.

This proposal concerns the 503B list and three drugs that are approved, where the agency's argument is precisely that approved versions already exist. A permissive direction on one does not imply a permissive direction on the other; if anything, the pairing shows FDA distinguishing between filling a gap where no approved product exists and duplicating one where it does. Our July 2026 PCAC review covers the other thread.

What to watch next

• The final determination. FDA must consider the comments before deciding. No timeline had been announced as of July 2026.
• Enforcement posture. How aggressively FDA pursues facilities still producing compounded GLP-1s will say more about near-term availability than the paperwork does.
• The oral entrants. Orforglipron's approval as Foundayo in April 2026 adds a small-molecule oral option that sidesteps peptide-synthesis supply constraints entirely, which changes the access argument over time.

Where this leaves things

The compounded GLP-1 era was built on a shortage exception, and it has been closing in stages since the shortages were resolved. This proposal is the step that would shut the remaining structural door at the outsourcing-facility level, and FDA's stated rationale is simple: approved products exist and are available, so the agency does not see a clinical need for bulk-compounded copies.

Until a final rule issues, the status is a proposal with a closed comment period, not settled law. But for anyone making decisions about access, the direction of travel has been consistent for two years, and betting on a reversal would be optimistic.